Search Result

Results for "

CCK Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cholecystokinin Receptor (57) Akt (3) CCR (1) Drug Isomer (1) Endogenous Metabolite (2) Ephrin Receptor (3) HIF/HIF Prolyl-Hydroxylase (3) Histone Methyltransferase (1) Interleukin Related (3) P-glycoprotein (2) Reference Standards (2) Sigma Receptor (1) VEGFR (3)
By Research Areas:	Cancer (15) Endocrinology (18) Inflammation/Immunology (4) Metabolic Disease (29) Neurological Disease (22)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Targets Recommended: Cholecystokinin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129357

CCK-B Receptor Antagonist 2	Cholecystokinin Receptor	Metabolic Disease
CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC₅₀ of 1.82 μM .

HY-118194

A-65186	Cholecystokinin Receptor	Others
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.

HY-B2154

Loxiglumide 4 Publications Verification CR-1505	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.

HY-125556

Tetragastrin 2 Publications Verification Cholecystokinin tetrapeptide; CCK-4	Cholecystokinin Receptor	Metabolic Disease
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .

HY-P2165

N-acetyl CCK-(26-30) amide CCK-(26-30) (sulfated)	Cholecystokinin Receptor	Neurological Disease
N-acetyl CCK-(26-30) amide (CCK-(26-30) (sulfated)) is a cholecystokinin (CCK) receptor antagonist .

HY-U00387

CCK-A receptor inhibitor 1	Cholecystokinin Receptor	Metabolic Disease Endocrinology
CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) *receptor* inhibitor with a binging IC₅₀ of 340 nM.

HY-129759

KSG-504 anhydrous	Cholecystokinin Receptor	Inflammation/Immunology
KSG-504 (anhydrous) is a **CCK receptor** antagonist. KSG-504 (anhydrous) inhibits the development of Ethionine-induced acute pancreatitis in rats and facilitates the regeneration of acinar cells .

HY-P2638

Cholecystokinin (27-32)-amide CCK-27-32-NH2	Cholecystokinin Receptor	Neurological Disease
Cholecystokinin (27-32)-amide (CCK-27-32-NH2) is a potent cholecystokinin receptor *CCK* receptor antagonist .

HY-129516

A-70874	Cholecystokinin Receptor	Metabolic Disease
A-70874 is a tyrosine-free tetrapeptide analog of cholecystokinin (30-33) (CCK-4). A-70874 is an agonist that stimulates pancreatic amylase release and a partial agonist that stimulates pancreatic phosphoinositide decomposition. A-70874 has an IC₅₀ of 4.9 nM for the guinea pig pancreatic CCK receptor. Cholecystokinin (CCK) receptors are divided into CCK-A (digestive tract) and CCK-B (brain). A-70874 has an affinity of 1.6 μM for the CCK-B/gastrin receptor .

HY-118546

JNJ-17156516	Cholecystokinin Receptor	Inflammation/Immunology
JNJ-17156516 is an orally active, potent, and selective cholecystokinin (CCK)1-receptor antagonist .

HY-123434

PD-149164	Cholecystokinin Receptor	Metabolic Disease Endocrinology
PD-149164 is a potent agonist of cholecystokinin B (CCK-B) receptor, with IC₅₀ values of 0.083 nM and 75 nM in binding assay to *CCK-B* and CCK-A .

HY-103355

YM022 2 Publications Verification	CCR	Metabolic Disease
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .

HY-100481

RP 72540 RPR101048	Cholecystokinin Receptor	Neurological Disease
RP 72540 is a selective *CCK-B* receptor antagonist, with IC₅₀ values of 2.4, 1.2, and 3.8 nM for *CCK-B* receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits *CCK-8*-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-U00363

CHEMBL333994 FK-480	Cholecystokinin Receptor	Endocrinology
CHEMBL333994 (FK-480) is a potent and orally active Cholecystokinin A receptor (CCK-A receptor) antagonist, with an IC₅₀ of 0.67 nM. CHEMBL333994 selectively antagonizes peripheral CCK receptors. CHEMBL333994 increases CCK mRNA level. CHEMBL333994 can be used for research of chronic pancreatitis .

HY-117839

PD-135666	Cholecystokinin Receptor	Neurological Disease
PD-135666 is a dipeptide inhibitor of cholecystokinin B (CCK B) receptors, binding to CCK B receptors in mouse cerebral cortex with IC50 of 0.1 nM. Its enantiomer, PD-140548, preferentially binds to CCK A receptors with IC50 of 2.8 nM in rat pancreas. PD-135666 exhibits anxiolytic effects in animal models .

HY-105226B

CI-988 hemihydrate PD134308 hemihydrate	Cholecystokinin Receptor	Neurological Disease Cancer
CI-988 hemihydrate (PD134308) is a potent, selective and orally active **CCK2R (cholecystokinin 2 receptor) antagonist with an IC₅₀** of 1.7 nM for mouse cortex CCK2. CI-988 hemihydrate shows >1600-fold selectivity for CCK2 over CCK1 receptor. CI-988 hemihydrate has anxiolytic and anti-tumor effects .

HY-105226

CI-988 PD134308	Cholecystokinin Receptor	Neurological Disease Cancer
CI-988 (PD134308) is a potent, selective and orally active **CCK2R (cholecystokinin 2 receptor) antagonist with an IC₅₀** of 1.7 nM for mouse cortex CCK2. CI-988 shows >1600-fold selectivity for CCK2 over CCK1 receptor. CI-988 has anxiolytic and anti-tumor effects .

HY-111918

A71378	Cholecystokinin Receptor	Metabolic Disease
A71378 is a selectivity **CCK-A receptor agonist the IC₅₀** values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC₅₀ = 0.16 nM) and ileal muscle contraction (EC₅₀ = 3.7 nM) .

HY-19261

T-0632	Cholecystokinin Receptor	Metabolic Disease
T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist.

HY-U00062

Tarazepide	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Tarazepide is a potent and specific *CCK-A* receptor antagonist.

HY-U00363A

(rac)-CHEMBL333994 (rac)-FK-480	Cholecystokinin Receptor Drug Isomer	Inflammation/Immunology
(rac)-CHEMBL333994 is the racemate of CHEMBL333994 (HY-U00363). CHEMBL333994 is a potent and orally active Cholecystokinin A receptor (CCK-A receptor) antagonist, with an IC₅₀ of 0.67 nM. CHEMBL333994 selectively antagonizes peripheral CCK receptors. CHEMBL333994 increases CCK mRNA level. CHEMBL333994 can be used for research of chronic pancreatitis .

HY-118665

L-736380	Cholecystokinin Receptor	Metabolic Disease
L-736380 is a high affinity **CCK-B (cholecystokinin B receptor)** receptor antagonist, with IC₅₀ values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID₅₀, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED₅₀, 1.7 mg/kg) .

HY-118314

CI-1015 PD 144598	Cholecystokinin Receptor	Cancer
CI-1015 is a potent CCK-B receptor antagonist.

HY-111313

JNJ-26070109	Cholecystokinin Receptor	Metabolic Disease
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pK_is of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .

HY-101764

Lintitript SR 27897	Cholecystokinin Receptor	Metabolic Disease
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC₅₀ of 6 nM and a K_i of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for *CCK1* than CCK2 receptors (EC₅₀ value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .

HY-B1439B

Lorglumide sodium salt CR-1409 sodium salt	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Lorglumide sodium salt (CR-1409 sodium salt) is a potent cholecystokinin (CCK) *receptor* antagonist .

HY-103354

Proglumide sodium 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Endocrinology Cancer
Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks *CCK*’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .

HY-B1330

Proglumide 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Endocrinology Cancer
Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks *CCK*’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .

HY-19445

Gastrazole JB95008	Cholecystokinin Receptor	Cancer
Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer .

HY-177506

FE100726	Cholecystokinin Receptor	Metabolic Disease
FE100726 (Compound 39) is a Cholecystokinin 2 (CCK2) receptor agonist. FE100726 has a superior binding capacity on CCK2 receptor. FE100726 can induce gastric acid secretion in anaesthetized rat models. FE100726 can be used for diabetes research .

HY-103354A

Proglumide hemicalcium	Cholecystokinin Receptor	Neurological Disease Endocrinology Cancer
Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks *CCK*’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .

HY-106840A

L-365260 hemihydrate 1 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain **CCK receptors** .

HY-U00360R

(Rac)-Sograzepide (Standard)	Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-U00360

(Rac)-Sograzepide (Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220	Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-121278

Benzotript Benzotriptum	Cholecystokinin Receptor	Inflammation/Immunology Cancer
Benzotript (Benzotriptum) is a cholecystokinin-receptor (CCK) and gastrin receptor antagonist. Benzotript shows antiproliferative effects in human colon carcinoma cell lines .

HY-101352

LY 225910	Cholecystokinin Receptor	Neurological Disease
LY 225910 is a selective antagonist for cholecystokinin receptor (CCK2 *receptor*), which affects the excitatory response to morphine, and leads to morphine sensitization .

HY-17617

Nastorazepide Z-360	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and *gastrin/CCK-2* receptor antagonist. Nastorazepide inhibits the specific binding of [ ³H]CCK-8 to the human CCK-2 receptor with a K_i value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .

HY-P1988

JMV 179	Cholecystokinin Receptor	Metabolic Disease
JMV 179, a peptide closely related to CCK, is a *cholecystokinin receptor* (CKK) antagonist, with an IC₅₀** of 30 nM .

HY-106301

Devazepide 4 Publications Verification L-364,718; MK-329	Cholecystokinin Receptor	Metabolic Disease
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC₅₀s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .

HY-103354R

Proglumide sodium (Standard)	Reference Standards Cholecystokinin Receptor	Neurological Disease Endocrinology Cancer
Proglumide (sodium) (Standard) is the analytical standard of Proglumide (sodium). This product is intended for research and analytical applications. Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .

HY-B1330R

Proglumide (Standard)	Cholecystokinin Receptor	Neurological Disease Endocrinology Cancer
Proglumide (Standard) is the analytical standard of Proglumide. This product is intended for research and analytical applications. Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .

HY-14850

Sograzepide Netazepide; YF 476; YM-220	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC₅₀ of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with K_i values of 0.068, 0.62 and 0.19 nM, respectively .

HY-14575

Nastorazepide hemicalcium Z-360 hemicalcium	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and *gastrin/CCK-2* receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [ ³H]CCK-8 to the human CCK-2 receptor with a K_i value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain .

HY-177507

FE101120	Cholecystokinin Receptor	Metabolic Disease
FE101120 is a non-peptide agonist **CCK2 receptor** agonist. FE101120 can be used for the study of diabetes .

HY-106356

GV-150013	Cholecystokinin Receptor	Others
GV-150013 is a selective *CCK-B* receptor antagonist. GV-150013 has sleep aid effect .

HY-P1097

Gastrin I, human Maximum Cited Publications 14 Publications Verification	Cholecystokinin Receptor	Endocrinology
Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

HY-177509

BBL454	Cholecystokinin Receptor	Metabolic Disease
BBL454 (Compound 43) is a Cholecystokinin 2B (CCK2B) receptor agonist. BBL454 induces hyperactivity and improves memory in rat models while it has weak activity on the peripheral CCK2 receptor and no anxiogenic activity. BBL454 increases gastric acid output in anesthetised rat models. BBL454 can be used for diabetes research .

HY-17617R

Nastorazepide (Standard)	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Standard) is the analytical standard of Nastorazepide. This product is intended for research and analytical applications. Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .

HY-106840

L-365260 1 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain **CCK receptors**. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .

Cat. No.	Product Name	Target	Research Area

HY-125556

Tetragastrin 2 Publications Verification Cholecystokinin tetrapeptide; CCK-4	Cholecystokinin Receptor	Metabolic Disease
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .

HY-P1097

Gastrin I, human 10+ Cited Publications	Cholecystokinin Receptor	Endocrinology
Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

HY-P2671

[Leu15]-Gastrin I (human)	Cholecystokinin Receptor	Cancer
[Leu15]-Gastrin I (human) is a Gastrin I, human (HY-P1097) peptide hormone derivative, which is trophic for normal gastrointestinal epithelium. Gastrin stimulates growth of gastric adenocarcinoma (gastric cancer) through G-protein-coupled receptor called the cholecystokinin (CCK) or cholecystokinin-B receptors (CCK-BR) that are overexpressed in this malignancy. [Leu15]-Gastrin I (human) is promising for research of gastric cancer .

HY-P3704

Enterostatin (rat)	Endogenous Metabolite	Metabolic Disease
Enterostatin (rat), an orally active activation peptide of procolipase, selectively reduces fat intake. Enterostatin (rat) reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism .

HY-P2165

N-acetyl CCK-(26-30) amide CCK-(26-30) (sulfated)	Cholecystokinin Receptor	Neurological Disease
N-acetyl CCK-(26-30) amide (CCK-(26-30) (sulfated)) is a cholecystokinin (CCK) receptor antagonist .

HY-P2638

Cholecystokinin (27-32)-amide CCK-27-32-NH2	Cholecystokinin Receptor	Neurological Disease
Cholecystokinin (27-32)-amide (CCK-27-32-NH2) is a potent cholecystokinin receptor *CCK* receptor antagonist .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-P1988

JMV 179	Cholecystokinin Receptor	Metabolic Disease
JMV 179, a peptide closely related to CCK, is a *cholecystokinin receptor* (CKK) antagonist, with an IC₅₀** of 30 nM .

HY-P2025

JMV 236	Histone Methyltransferase	Neurological Disease
JMV 236 is a cholecystokinin antagonist with appetite-suppressing activity. JMV 236 affects the regulation of food intake through the interaction of the intestinal endogenous peptide PrRP and the CCK1 receptor. The administration of JMV 236 activates PrRP neurons located in the NTS, thereby enhancing its appetite-suppressing effect. JMV 236 has significant effects on areas of the central nervous system associated with food intake, especially during states of starvation .

Species:	Human (2)
Tag:	His (2)
Source:	P. pastoris (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P700624

	RIPK2 Protein, Human (P. pastoris, His) Receptor-interacting serine-threonine kinase 2; Receptor-interacting serine/threonine-protein kinase 2; CARD3; CARDIAK; RICK; RIP2; RIP-2; CARD-carrying kinase; growth-inhibiting gene 30; tyrosine-protein kinase RIPK2; Receptor interacting protein 2; Receptor-interacting protein 2; RIP-like-interacting CLARP kinase; CARD-containing IL-1 beta ICE-kinase; CARD-containing interleukin-1 beta-converting enzyme-associated kinase; CARD-containing interleukin-1 beta-converting enzyme (ICE)-associated kinase; Receptor-interacting protein (RIP)-like interacting caspase-like apoptosis regulatory protein (CLARP) kinase; CCK; GIG30;	Human	P. pastoris
	RIPK2 is a multifunctional serine/threonine/tyrosine protein kinase that coordinates innate and adaptive immune responses. It is activated by bacterial peptidoglycan to form filaments in the NOD1 and NOD2 pathways, undergoing autophosphorylation and polyubiquitination. RIPK2 Protein, Human (P. pastoris, His) is the recombinant human-derived RIPK2 protein, expressed by P. pastoris , with C-6His, C-6His labeled tag.

HY-P72166

	DBI Protein, Human (103a.a, His) ACBD1; ACBP; ACBP_HUMAN; Acyl CoA binding domain containing 1; Acyl CoA binding protein; Acyl Coenzyme A binding domain containing 1; Acyl coenzyme A binding protein; Acyl-CoA-binding protein; CCK RP; CCKRP; Cholecystokinin releasing peptide trypsin sensitive; DBI; Diazepam-binding inhibitor; Endozepine; EP; GABA Receptor modulator; MGC70414	Human	E. coli
	DBI, a versatile protein, binds medium- and long-chain acyl-CoA esters, indicating a potential intracellular carrier role. It also displaces diazepam from the benzodiazepine recognition site on the GABA type A receptor. This dual functionality suggests DBI may act as a neuropeptide, modulating GABA receptor activity. Remarkably, DBI functions as a monomer in these interactions. DBI Protein, Human (103a.a, His) is the recombinant human-derived DBI protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P85079

	CCK-4 Antibody (YA4771) PTK7; CCK4; Inactive tyrosine-protein kinase 7; Colon carcinoma kinase 4; CCK-4; Protein-tyrosine kinase 7; Pseudo tyrosine kinase Receptor 7; Tyrosine-protein kinase-like 7	WB, IHC-P, ICC/IF, ELISA	Human
	CCK-4 Antibody (YA4771) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CCK-4.

HY-P87052

	RIPK2 Antibody (YA6745) CARD 3 antibody; CARD carrying kinase antibody; CARD containing ICE associated kinase antibody; CARD containing IL 1 beta ICE kinase antibody; CARD containing IL1 beta ICE kinase antibody; CARD containing interleukin 1 beta converting enzyme (ICE) associated kinase antibody; CARD containing interleukin 1 beta converting enzyme associated kinase antibody; CARD-containing IL-1 beta ICE-kinase antibody; CARD-containing interleukin-1 beta-converting enzyme-associated kinase antibody; CARD3 antibody; CARD 3 antibody; CARD carrying kinase antibody; CARD containing ICE associated kinase antibody; CARD containing IL 1 beta ICE kinase antibody; CARD containing IL1 beta ICE kinase antibody; CARD containing interleukin 1 beta converting enzyme (ICE) associated kinase antibody; CARD containing interleukin 1 beta converting enzyme associated kinase antibody; CARD-containing IL-1 beta ICE-kinase antibody; CARD-containing interleukin-1 beta-converting enzyme-associated kinase antibody; CARD3 antibody; CARDIAK antibody; CCK antibody; CLARP kinase antibody; GIG 30 antibody; GIG30 antibody; Growth inhibiting gene 30 antibody; Receptor interacting protein (RIP) like interacting caspase like apoptosis regulatory protein (CLARP) kinase antibody; Receptor interacting protein 2 antibody; Receptor interacting serine threonine kinase 2 antibody; Receptor interacting serine/threonine protein kinase 2 antibody; Receptor-interacting protein 2 antibody; Receptor-interacting serine/threonine-protein kinase 2 antibody; RICK antibody; R; IP : 2 antibody; R; IP : like interacting CLARP kinase antibody; RIP-2 antibody; RIP-like-interacting CLARP kinase antibody; RIPK 2 antibody; Ripk2 antibody; RIPK2_HUMAN antibody; TNFRSF antibody; Tyrosine-protein kinase RIPK2 antibody; UNQ277/PRO314/PRO34092 antibody;	WB	Human
	RIPK2 Antibody (YA6745) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIPK2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: